BMO vs ITUB

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score prevents a full solvency risk assessment. Despite solid profitability metrics like a 38.67% operating margin and strong revenue growth of 15.50%, earnings growth is inconsistent, with recent Q/Q declines and volatile quarterly surprises. The stock trades above its Graham defensive value of $127.87 at $137.69, yet below the analyst target of $127.91, while offering a solid 3.45% dividend yield with a sustainable 56.29% payout ratio. Technical trend sentiment is weak at 10/100, offsetting positive insider sentiment, resulting in a neutral overall stance.

ITUB presents a contradictory profile: while it maintains a strong ROE of 21.01% and trades near its intrinsic value of $8.96, its deterministic health is severely compromised with a Piotroski F-Score of 2/9. The stock is currently priced at a slight premium to the Graham Number ($8.18) and above the average analyst target price of $8.36. Despite strong historical 1-year price appreciation (+60.3%), the current technical trend is heavily bearish (10/100), suggesting a potential reversal or consolidation phase. The combination of weak fundamental health scores and a high dividend payout ratio offsets the company's dominant market position.